Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia.
Adult
Aged
Area Under Curve
Bernard-Soulier Syndrome
/ blood
Blood Platelets
/ chemistry
Cellular Senescence
Diagnosis, Differential
Female
Flow Cytometry
/ methods
Humans
Male
Middle Aged
P-Selectin
/ blood
Pilot Projects
Platelet Activation
Platelet Count
Purpura, Thrombocytopenic, Idiopathic
/ blood
ROC Curve
Sensitivity and Specificity
Sialic Acids
/ blood
Thrombocytopenia
/ blood
Flow cytometry
Immature platelet fraction
Immune thrombocytopenia
Inherited thrombocytopenia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
13
05
2021
accepted:
18
08
2021
pubmed:
15
9
2021
medline:
26
10
2021
entrez:
14
9
2021
Statut:
ppublish
Résumé
Immune thrombocytopenia (ITP) is an acquired bleeding disorder, for which no specific diagnostic test exists. Inherited thrombocytopenia (IT) can mimic ITP and lead to unappropriated management with significant morbidity. Here, in small cohorts of these two disorders, we explored whether platelet sialylation and platelet activation could allow to discriminate the two conditions. We also aimed to confirm the value of immature platelet counts in this discrimination. Platelet sialylation and the expression level of P-selectin were assessed by multiparameter flow cytometry. Immature platelets were estimated on a Sysmex XN 9000 analyzer. No significant difference in platelet sialylation was observed between ITP and IT. Contrarily, platelet activation was significantly higher in ITP patients (p = 0.008). The immature platelet fraction, as previously demonstrated, was significantly lower in the ITP group compared to the IT group (p = 0.014). That statistical significance was achieved in this small pilot study suggests that the two easily available assays of immature platelet count and P-selectin expression could help physicians to reach the proper diagnosis in complex cases of thrombocytopenia.
Identifiants
pubmed: 34519886
doi: 10.1007/s00277-021-04651-4
pii: 10.1007/s00277-021-04651-4
doi:
Substances chimiques
P-Selectin
0
SELP protein, human
0
Sialic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2677-2682Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829–3866. https://doi.org/10.1182/bloodadvances.2019000966
doi: 10.1182/bloodadvances.2019000966
pubmed: 31794604
pmcid: 6963252
Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE, Sykes DB, Kuter DJ (2020) A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv 4:9–18. https://doi.org/10.1182/bloodadvances.2019000868
doi: 10.1182/bloodadvances.2019000868
pubmed: 31891657
Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, Kelton JG (2017) Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 1:2414–2420. https://doi.org/10.1182/bloodadvances.2017010942
doi: 10.1182/bloodadvances.2017010942
pubmed: 29296891
pmcid: 5729626
Miltiadous O, Hou M, Bussel JB (2020) Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 135:472–490. https://doi.org/10.1182/blood.2019003599
doi: 10.1182/blood.2019003599
pubmed: 31756253
pmcid: 7484752
Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM (2015) The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 21:47–54. https://doi.org/10.1038/nm.3770
doi: 10.1038/nm.3770
pubmed: 25485912
Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M et al (2015) Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 6:7737. https://doi.org/10.1038/ncomms8737
doi: 10.1038/ncomms8737
pubmed: 26185093
Revilla N, Corral J, Miñano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I et al (2019) Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets 30:743–751. https://doi.org/10.1080/09537104.2018.1513476
doi: 10.1080/09537104.2018.1513476
pubmed: 30296193
Tao L, Zeng Q, Li J, Xu M, Wang J, Pan Y, Wang H, Tao Q, Chen Y, Peng J et al (2017) Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. J Hematol Oncol 10:46. https://doi.org/10.1186/s13045-017-0413-3
doi: 10.1186/s13045-017-0413-3
pubmed: 28179000
pmcid: 5304552
Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, Shao L, Hou Y, Min Y, Kong Z et al (2016) CD8+ T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep 6:27445. https://doi.org/10.1038/srep27445
doi: 10.1038/srep27445
pubmed: 27321376
pmcid: 4913243
Fouassier M, Babuty A, Debord C, Béné MC (2020) Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints. Cytometry B Clin Cytom 98:464–475. https://doi.org/10.1002/cyto.b.21892
doi: 10.1002/cyto.b.21892
pubmed: 32516490
Benlachgar N, Doghmi K, Masrar A, Mahtat EM, Harmouche H, Tazi MZ (2020) Immature platelets: a review of the available evidence. Thromb Res 195:43–50. https://doi.org/10.1016/j.thromres.2020.06.048
doi: 10.1016/j.thromres.2020.06.048
pubmed: 32652352
Ferreira FLB, Colella MP, Medina SS, Costa-Lima C, Fiusa MML, Costa LNG, Orsi FA, Annichino-Bizzacchi JM, Fertrin KY, Gilberti MFP et al (2017) Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Sci Rep 7:3355. https://doi.org/10.1038/s41598-017-03668-y
doi: 10.1038/s41598-017-03668-y
pubmed: 28611471
pmcid: 5469896
Miyazaki K, Koike Y, Kunishima S, Ishii R, Danbara M, Horie R, Yatomi Y, Higashihara M (2015) Immature platelet fraction measurement is influenced by platelet size and is a useful parameter for discrimination of macrothrombocytopenia. Hematology 20:587–592. https://doi.org/10.1179/1607845415Y.0000000021
doi: 10.1179/1607845415Y.0000000021
pubmed: 26035037
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393. https://doi.org/10.1182/blood-2008-07-162503
doi: 10.1182/blood-2008-07-162503
pubmed: 19005182
Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, Montero VS, Rabinovich GA, Molinas FC et al (2019) Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep 9:2208. https://doi.org/10.1038/s41598-018-38086-1
doi: 10.1038/s41598-018-38086-1
pubmed: 30778108
pmcid: 6379541
Revel-Vilk S, Shai E, Turro E, Jahshan N, Hi-Am E, Spectre G, Daum H, Kalish Y, Althaus K, Greinacher A et al (2018) GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting. Blood 132:1851–1854. https://doi.org/10.1182/blood-2018-04-845545
doi: 10.1182/blood-2018-04-845545
pubmed: 30171045
pmcid: 6202914
Kauskot A, Pascreau T, Adam F, Bruneel A, Reperant C, Lourenco-Rodrigues MD, Rosa JP, Petermann R, Maurey H, Auditeau C et al (2018) A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation. Haematologica 103:e613–e617
doi: 10.3324/haematol.2018.198028
Cahill MR, Macey MD, Cavenagh JD, Newland AC (1998) Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol 100:358–364. https://doi.org/10.1046/j.1365-2141.1998.00568.x
doi: 10.1046/j.1365-2141.1998.00568.x
pubmed: 9488627
Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, Bussel JB (2011) Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 117:5723–5732. https://doi.org/10.1182/blood-2010-11-321398
doi: 10.1182/blood-2010-11-321398
pubmed: 21389318
pmcid: 3110029
Lev PR, Grodzielski M, Goette NP, Glembotsky AC, Espasandin YR, Pierdominici MS et al (2014) Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Br J Haematol 165(6):854–64. https://doi.org/10.1111/bjh.12832
doi: 10.1111/bjh.12832
pubmed: 24673454